Cargando…
Nanoscale Au@SiO(2)-drug/VEGF as an in vivo probe for osteosarcoma diagnosis and therapy
Osteosarcoma is a common primary bone malignancy, with a 5-year survival rate of only 20–30% in patients undergoing surgical treatment. Thus, it is important to identify novel methods for diagnosing and treating osteosarcoma, which was the aim of the present study. Vascular endothelial growth factor...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442140/ https://www.ncbi.nlm.nih.gov/pubmed/34589145 http://dx.doi.org/10.3892/ol.2021.13027 |